NASDAQ:PTIX

Protagenic Therapeutics . Common Stock Stock Insider Trading

etoro logo Buy PTIX
*Your capital is at risk
$0.180
+0.0134 (+8.02%)
At Close: Jul 31, 2026

Protagenic Therapeutics . Common Stock Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 8.63M and sold 0 PTIX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
0
Buy 8.63M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Nov 05, 2019
Buy
Convertible Note
P-Purchase
Barrage Khalil
Director
Director 0
Value: $0
Nov 05, 2019
Buy
Convertible Note
P-Purchase
Barrage Khalil
Director
Director 0
Value: $0
Mar 20, 2019
Buy
PTIX Common stock Options
A-Award
Arrow Alexander K.
Chief Financial Officer
C-Suite Officer 41 667
Value: $41.7K
Mar 20, 2019
Buy
PTIX Common stock Options
A-Award
Arrow Alexander K.
Chief Financial Officer
C-Suite Officer 41 667
Value: $41.7K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Corvese Brian
Director
Director 95 000
Value: $166.3K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Arrow Alexander K.
Chief Financial Officer
C-Suite Officer 75 000
Value: $131.3K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Armen Garo H
Executive Chairman
CEO / President 250 000
Value: $437.5K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy()
A-Award
Stein Robert Benjamin
Director
Director 200 000
Value: $350.0K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Silverman Joshua
Director
Director 45 000
Value: $78.8K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Barrage Khalil
Director
Director 45 000
Value: $78.8K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Barrage Khalil
Director
Director 45 000
Value: $78.8K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Silverman Joshua
Director
Director 45 000
Value: $78.8K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy()
A-Award
Stein Robert Benjamin
Director
Director 200 000
Value: $350.0K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Armen Garo H
Executive Chairman
CEO / President 250 000
Value: $437.5K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Arrow Alexander K.
Chief Financial Officer
C-Suite Officer 75 000
Value: $131.3K
Oct 16, 2017
Buy
Non-Qualified Stock Options (Right to Buy)
A-Award
Corvese Brian
Director
Director 95 000
Value: $166.3K
Aug 08, 2016
Buy
NSO Stock Option
A-Award
Barrage Khalil
Director
Director 150 000
Value: $187.5K
Aug 08, 2016
Buy
NSO Stock Option
A-Award
Barrage Khalil
Director
Director 150 000
Value: $187.5K
Jun 17, 2016
Buy
Common Stock
P-Purchase
Armen Garo H
See Remarks
Officer 60 211
Value: $75.3K
Jun 17, 2016
Buy
Common Stock
P-Purchase
Armen Garo H
See Remarks
Officer 60 211
Value: $75.3K
Jun 17, 2016
Buy
NSO Stock Option
A-Award
Ekizian Gregory
Director
Director 45 000
Value: $56.3K
Jun 17, 2016
Buy
NSO Stock Option
A-Award
Ekizian Gregory
Director
Director 45 000
Value: $56.3K
Jun 17, 2016
Buy
NSO Stock Option
A-Award
Arrow Alexander K.
Chief Financial Officer
C-Suite Officer 140 000
Value: $175.0K
Jun 17, 2016
Buy
NSO Stock Option
A-Award
Armen Garo H
See Remarks
Officer 500 000
Value: $625.0K
Jun 17, 2016
Buy
NSO
A-Award
Silverman Joshua
Director
Director 45 000
Value: $56.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT PROTAGENIC THERAPEUTICS, INC. COMMON STOCK
Protagenic Therapeutics . Common Stock
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York....
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE